COVID VACCINE MANUFACTURER’S LIABILITY, ILLEGAL MANDATES AND HUMAN RIGHTS VIOLATIONS

COVID VACCINE MANUFACTURER’S LIABILITY, ILLEGAL MANDATES AND HUMAN RIGHTS VIOLATIONS

On June 22, 2023, in the United States District Court for the Southern District of Florida, the Court in which President Trump stands indicted, Drs. David Basch and Richard Arjun Kaul filed a lawsuit (Kaul/Basch v Federation: 23-CV-22325) (K11-14) against, amongst others, Defendant Federation of State Medical Boards and 2024 US Presidential candidate, Christopher J. Christie, on racketeering charges pertaining to injuries caused by the so called COVID ‘vaccine’:

“The most recent catastrophe is that related to the mass forced/coerced inoculations of the American public with an mRNA toxin, that the public was deceived into believing was a ‘vaccine’ against COVID-19. This gene manipulating toxin has resulted and will continue to result in, amongst other things, premature death, increased rates of cancer, cardiac disease, and early-onset dementia/neuro-cognitive deterioration.”

 “Commencing in early 2020, just after the announcement of the purported pandemic, Plaintiff Kaul began writing articles and filing legal documents that highlighted the multiple profit purposed COVID related frauds that mandated knowingly toxic and ineffective mRNA ‘vaccines’, the wearing of masks and ubiquitous, but non-specific PCR testing.”

 “In a time period commencing in or around May 2020, Defendant FSMB-FBM/agents in collusion and conspiracy with co-conspirators Pfizer/Moderna/agents and others did order American state medical boards and coerce foreign medical councils to compel, under penalty of license suspension/revocation and or medical registration suspension/erasure, its physicians to deceive patients into being inoculated with an mRNA compound that patients were falsely led to believe was a vaccine against COVID, but that Defendant FSMB-FBM and its corporate/state medical board co-conspirators knew was not only not a vaccine, but a substance with immense/lethal toxicity.”

 Crimes Against Humanity: Defendant FSMB-FBM and its ‘vaccine’ manufacturer co-conspirators CEO Joaquin Duato/Agents (Johnson + Johnson) CEO Albert Bourla/Agents (Pfizer), Pascal Soriot/Agents (Astra Zeneca) and CEO Stephane Bancel/Agents (Moderna), knew that the ‘vaccine’ was toxic and ineffective, and that it would cause death, permanent injury, and generational injury in that ‘vaccine’ caused genetic mutations/injuries would be transmitted in reproduction.”

 

On June 14, 2023, there was a second attempt on Kaul’s life and liberty, the first being on May 27, 2021.

On this episode of Real Pain, Real Talk: APDF patients and advocates, Bob Sheerin & Andrew Hohenthaner, to talk about how pain impacts

Episode 2. On this episode of Real Pain, Real Talk, our Host,
Kat Hatz, is joined by two fellow APDF patients and advocates, Bob Sheerin
& Andrew Hohenthaner, to talk about how pain impacts everything, from
functionality to basic quality of life. We discuss our journeys as patients and
advocates, both before and after the Centers for Disease Control &
Prevention (CDC) issued draconian Guidelines for Prescribing Opioids in 2016,
which were revised in 2022 but with no substantive improvements. We also talk
about the heartbreak involved when we advocate for a community we belong to,
that consists of extremely vulnerable, disabled, and marginalized individuals.
We try to raise awareness about how hard it is to know we will continue to lose
members of our community until substantive changes are made to the harmful and
widely adopted current policies pertaining to pain medicine. In addition, we
discuss how those policies have hurt us and countless other patients. We hope
this episode is heard by both the pain community and healthy people, as we try
to give a voice to people who face intractable chronic pain. Please tune in and
help us debunk a flawed media narrative that has been pushed by government
agencies, legislators, insurers, and others, and which has resulted in millions
of preventable harms and deaths that pain patients have sustained. Follow our
podcast, and you will immediately be notified when a new episode is out!

Another group of bureaucrats being formed to created prescribing limits on controlled meds

More bureaucratic control over the prescribing of controlled meds in KENTUCKY.  If you are interested click on this link  

lists a whole array of practitioners licensed in KY to prescribe controlled substances. One thing I find interesting is according to the CSA NO ONE can prescribe a controlled substance without doing a IN PERSON PHYSICAL EXAM.  What I also find interesting is that most of the pts prescribed controlled substances are – or could be – a covered entity under the Americans with Disability Act and perhaps any laws, rules, or regulations that would place a limit on the mgs/day or some sort of other limitations of therapy. Besides, the FDA has established all those daily limits already!
Besides, most all controlled meds are prescribed with pts dealing with subjective diseases and there is no lab or other test to determine the impact of the disease on the pt’s QOL.
If these “dosage recommendations” come out without some sort of reference to pharmacogenomic testing on individual pts, and/or using the “junk science” MME system, they will not be using current pharmaceutical knowledge on appropriate prescribing.
Also, notice on the list of who is going to be on this committee – NOT ONE – chronic pain pt.  Human Psychology suggests that a person cannot truly understand certain things — unless they have personally experienced certain issues.
Date:                  June 22, 2023
TO:                      All Kentucky licensed pharmacists
FROM:               Christopher Harlow, Pharm. D., R.Ph.
                             Executive Director
RE:                       Controlled Substances Prescribing Council
Senate Bill 94 enacted during the 2023 Regular Session creates the Controlled Substances Prescribing Council under the Office of Inspector General. See Section 2 of the bill, which was codified as KRS 218A.025.
KRS 218A.025(1)(h) provides that the Kentucky Board of Pharmacy will select one licensed pharmacist to serve as a member of the Council. The Council will meet at least quarterly “to discuss matters relating to the safe and appropriate prescribing and dispensing of controlled substances.”
Members will be selected by the Board from applications submitted by interested individuals.  If interested, please submit the completed application along with a resume or curriculum vitae [CV] to the Board office by mail, email, or fax.
Please return your completed application to the Board office by close of business July 19, 2023. Please enclose a copy of your resume or curriculum vitae [CV].
If you have further questions, please contact the Executive Director at christopher.harlow@ky.gov
Thank you,
Kentucky Board of Pharmacy

Effective July 1, Florida Will Prohibit Offshore Storage of Health Records and Require Additional Ownership Disclosures

Effective July 1, Florida Will Prohibit Offshore Storage of Health Records and Require Additional Ownership Disclosures

https://www.lexology.com/library/detail.aspx

A new Florida law will require certain Florida-licensed providers to ensure that patient information is physically maintained only in the continental United States and its territories or in Canada. Florida SB 264, which goes into effect July 1, 2023, amends the Florida Electronic Health Records Exchange Act, adding a ban on offshoring health information that goes beyond the requirements under HIPAA and most other generally applicable health privacy and security laws. Florida licensees to which the new requirements apply will need to attest upon initial licensure and any renewals that they are in compliance with the new requirements. Applicable licensees will also be required to ensure that no individual or entity with a controlling interest in the licensee has an interest in an entity that has a business relationship with certain foreign countries, as discussed below.

The new privacy requirements apply to all “qualified electronic health records that are stored using technology that can allow information to be electronically retrieved, accessed or transmitted” used by the categories of health care providers listed below. “Qualified electronic health records” are electronic health records that can provide clinical decision support, support physician order entry, capture and query relevant quality information, and exchange electronic health information with and from other sources. The new anti-offshoring requirements are separate from the recently passed Florida Digital Bill of Rights, which our Mintz privacy colleagues covered here.

Impacted provider types encompass facilities including, but not limited to, hospitals, clinics, ambulatory surgical centers, home health agencies, hospices, nursing homes, labs, pharmacies, and individual practitioners including physicians, physician assistants, advanced practice registered nurses, registered nurses, pharmacists, dentists, chiropractors, podiatrists, certain behavioral health providers, physical therapists, occupational therapists, speech-language pathologists, audiologists, and respiratory therapists. The law only applies to providers who use “certified electronic health record technology”, or CEHRT, which meets the federal interoperability standards. Because of ambiguity in the statute, it is unclear if the law is meant to apply only to providers who participate in the CMS payment programs that require CEHRT or if the requirements are more broadly applicable to any provider who utilizes CEHRT, regardless of whether they are required to do so.

The new licensure requirements included in the statute require providers applying for and renewing their Florida Agency for Health Care Administration (AHCA) licensure to submit an affidavit attesting under penalty of perjury that the applicant is in compliance with the prohibition on offshoring health care information. Failure to maintain compliance with the requirements could result in disciplinary action by AHCA.

The requirement to store qualified electronic health records within the U.S. and Canada also extends to third-party vendors and subcontractors who store such records on behalf of the affected Florida providers. This could also affect vendors overseas who access electronic health records if the access involves downloading a copy of the records. Because of the potential reach of this law, providers operating in Florida should take steps to confirm that neither they nor their vendors are storing electronic health records outside of the U.S. and Canada.

While HIPAA does not prohibit offshoring health information, covered entities outside of Florida should always take steps to ensure that vendors who store PHI offshore are able to comply with all of the privacy and security requirements under HIPAA and other applicable privacy laws. Third-party payers, including Medicare Advantage plans and state Medicaid programs, also often include provisions restricting or prohibiting the use of offshore vendors, so providers should stay on top of how and where their health records are being stored.

The new law also requires entities licensed by AHCA to confirm that no individual or entity with a controlling interest in the licensed entity holds, directly or indirectly, an interest in an entity that does business with a “foreign country of concern.” “Foreign countries of concern” include “the People’s Republic of China, the Russian Federation, the Islamic Republic of Iran, the Democratic People’s Republic of Korea, the Republic of Cuba, the Venezuelan regime of Nicolás Maduro, or the Syrian Arab Republic, including any agency of or any other entity of significant control of such foreign country of concern.” Under Florida law, a controlling interest is defined to mean a person or entity that serves as an officer or director of or has a 5% or greater ownership interest in the licensee or a management company that manages the licensee. The law as drafted does not include a carve-out for ownership interests held by publicly traded entities, unlike the current ownership limitations related to holding an interest in a facility that has previously had its license revoked. Notably, as drafted the restrictions do not include any carve out for activities that the Office of Foreign Assets Control has permitted to be conducted with sanctions nations. Additionally, the inclusion of the People’s Republic of China in the list of foreign countries of concern will require entities licensed in Florida to review potential business relationships that they or their parent companies have in China that are otherwise permissible under U.S. law.

It has not been well disclosed that Experian owns Narxcare and that Experian HQ is in Ireland and that they are storing all of the health information databases off-shore, because that makes those databases outside of our HIPAA laws.  Some have compared the collecting and selling of data to the “California gold rush” in the mid 19th century

HERSH PATEL, MD: THE BOTHRA TRIAL, HOW DEFENSE ATTY LAWRENCE MARGOLIS EXPOSED DEA EXPERT PATEL AS A COMPLETE FRAUD

Pain physician Hersh Patel MD captured authoring fraudulent EMR note with “cut and paste” medical history. He documented a physical exam that never happened. Also documented advising patient about risks of opioids, risks,alternatives etc. etc that never actually happened.  Hersh Patel MD, straight out of his pain fellowship training, telling elderly folks that they can be arrested for taking their physician-prescribed FDA approved opioid

 

HERSH DINESH PATEL MD., FALSE UNO-FALSE OMNIBUS “WHEN A GOVERNMENT WITNESS LIES THEY MUST LOSE THEIR MEDICAL LICENSE: A COMPLAINT BEFORE DELAWARE MEDICAL BOARD

 

THE MYTH OF MORPHINE MILLIGRAM EQUIVALENT DAILY DOSE: NABARUN DASGUPTA et al. DOES THE MATH

Dr. Naburun Dasgupta informative lecture on the falsehood of the Morphine Milligram Equivalent and calls into question the Prosecution of healthcare providers by the US Attorney General and the Department of Justice and DEA in the use of Narcotic Analgesic Medications (Opioids)

reported by norman j clement rph., dds

THE MYTH OF MORPHINE MILLIGRAM EQUIVALENT DAILY DOSE

In 2016, the CDC issued its Guidelines for Prescribing Opioids for Chronic Pain Patients. In publishing the guidelines, the CDC explicitly stated that they were meant to be voluntary and “not prescriptive,” stating that healthcare practitioners knew their patients’ unique clinical situation and should weigh the potential risks and benefits when prescribing opioids. Many of its recommendations were based on what the CDC characterized as “Type 3” or “Type 4” evidence, which are categories of evidence that are less probative and carry a significant risk of inaccuracy. The guidelines thus came under significant criticism from many pain and addiction specialists for lacking a strong basis in the evidence.

Others criticized the use of morphine milligram equivalents (MMEs) in determining the appropriate dosing of different opioids. As Fudin and others have argued, MME dosing was designed in an attempt to examine opioids with similar analgesic effects and should not be used to determine an exact mathematical dosing conversion.

“MME IS NOT A STANDARDIZE CLINICAL METRIC”

The pharmacology and unique properties of each opioid and patient individuality must be considered when a therapeutic opioid conversion is contemplated. Conversion should not simply rely on a mathematical formula embedded within the CDC calculator software.

Furthermore, the current calculation for methadone employed by the calculator could allow for potentially dangerous conversions. This is especially problematic, considering this calculator is intended to target nonspecialist general practitioners. We expect a higher level of scientific accuracy and integrity from an agency entrusted to protect citizens’ health and welfare.

Recognizing the controversy surrounding MMEs, in August 2021, the FDA held a “public workshop” entitled “Morphine Milligram Equivalents: Current Applications and Knowledge Gaps, Research Opportunities, and Future Directions.” The workshop’s stated purpose was to “provide an understanding of the science and data underlying existing MME calculations for opioid analgesics, discussing the gaps in these data, and discussing future directions to refine and improve the scientific basis of MME applications.”

DONATE LEGAL DEFENSE

OR SEND

$10, $15, $20, $25,$50, $75, 175, $500. OR MORE TO CASH APP:$docnorm

ZELLE 3135103378 or Donate to the “Pharmacist For Healthcare Legal Defense Fund,

NABARUN DASGUPTA et al.DOES THE MATH

During the workshop, Nabarun Dasgupta of the University of North Carolina Injury Prevention Research Center presented research stating: “Contrary to conventional wisdom, conversion values are not based on pharmacologic properties. Instead, they arose 60 years ago from small single-dose clinical studies in post-operative or cancer populations with pain score outcomes; toxicologic effects (e.g., respiratory depression) were not evaluated.”

The research concluded: “The overlooked inconsistency among daily MME definitions revealed by our study calls into question the clinical validity of a single numerical risk threshold. . . . Our findings call into question state laws and third-party payer MME threshold mandates. Without harmonization, the scientific basis for these mandates may need to be revisited.”86 Some critics consider the use of MMEs to be “junk science.”

Nevertheless, many states implemented statutory or regulatory limits on the dose (in MMEs) and number of opioids that may be prescribed to patients in acute, chronic, and postoperative situations, respectively, and they encouraged policies promoting the rapid or abrupt tapering of chronic pain patients off the opioid therapies on which they had been maintained long-term.

In 2018, Oregon proposed a mandatory reduction to zero opioids calculation for methadone employed by the calculator could allow for potentially dangerous conversions. This is especially problematic, considering this calculator is intended to target nonspecialist general practitioners. We expect a higher level of scientific accuracy and integrity from an agency entrusted to protect citizens’ health and welfare in Medicaid patients over 12 months. The state reversed itself after receiving fierce criticism from pain management and addiction specialists.

 

for now, youarewithinthenorms.com

 

 

REBECCA DELFINO: WHO IS SHE AND WHY IS MS. DELFINO ONE OF AMERICA’S MOST DANGEROUS LAW PROFESSORS IN PAIN MANAGEMENT HEALTHCARE POLICY, PART-1

Many of Delfino’s assertions regarding the evolution of drug regulation in the United States are either inaccurate or lacking nuance. For example, the Article states that the Opium Exclusion Act of 1909 “was the first government regulation of opioids.” Delfino, supra note 4, at 354. While this law was the first federal prohibition on opiate use, Congress had previously regulated opiate availability through taxation and tariffs, see Audrey Redford & Benjamin Powell, Dynamics of Intervention in the War on Drugs:

 

WARNING!!! WARNING!!! WARNING!!! TO ALL PROVIDERS AND PATIENTS: MEET REBECCA DELFINO, AMERICA’S MOST DANGEROUS LAW PROFESSOR AND PAIN HEALTHCARE POLICY MAKER; Part-1

 

JUSTICE FOR DR. RANDY LAMARTINIERE, MD…FREE DR. RANDY NOW!!!!

Dr. Randy Lamartiniere, MD, did everything by the book, as we all do. He monitored their care with drug screens and conducted reevaluations every three months for his very reasonable standard medical fee without any added charges for pain management. And got 15 years Fed Prison by one of America’s most Corrupt Federal Judge in America’s Most Corrupt Judicial Circuit. “No Justice, No Peace…Free Dr. Randy Now!!!

 

ANOTHER SAD DAY IN MEDICINE: CORRUPT FEDERAL JUDGE BRIAN JACKSON GIVES 15 YEARS OF FEDERAL PRISON TIME TO DR. RANDY LAMARTINERE, MD, FOR PRACTICING MEDICINE!!! **!!PLATO HEALTH INTEGRITY’S VENDOR FRAUD!!!**

 

DR. SHIVA AKULA, MD LOVES AMERICA IS AN HERO, SAVED LIVES DURING COVID-19 PANDEMIC, HOWEVER!?..

DR. SHIVA AKULA, MD “AN AMERICAN HERO:” THE DEPARTMENT OF JUSTICE TARGETING OF SUCCESS, AND FACING A REALITY OF, ‘PRACTICING MEDICINE WHILE BROWN’ IN AMERICA’

The lawsuit details the method of the conspiracy and how the criminal indictment is purposed to eliminate Dr. Akula from the American healthcare market to permit his competitors to seize his business and personal assets:“ The indictment and subsequent prosecution were a consequence of a conspiracy concocted by Defendants Passages, Anderson, and co-conspirator William Cassidy, Esq, all of whom stood to profit at the expense of Plaintiff Akula, through respectively, increased market share by eliminating Akula and seizing his business assets, a ‘whistleblower’ fee, and legal fees for Plaintiff Akula’s criminal defense.”

AMERICA HAS BEEN BAMBOOZLED BY BAMBOO HEALTH (PDMP) NARXCARE SOFTWARE

Norman J. Clement RPh., DDS, MS; BAMBOOZLED BY BAMBOO HEALTH: Our group and writers of youarewithinthenorms.com and Pronto Pharmacy LLC, Tampa Fl are in full support of the Citizen Petition Submitted by the Center for U.S. Policy to request the Commissioner of the U.S. Food and Drug Administration (“FDA”) to deem the Bamboo Health (“Bamboo”) NarxCare software a misbranded device and take administrative action to prevent serious, adverse health consequences and death. We further demand the immediate removing this dangerous software from all Healthcare Systems.

 

LETTER TO FDA: IN SUPPORT OF CENTER FOR U.S. POLICY PETITION FOR IMMEDIATE TERMINATION OF DEA’s NARXCARE AND PDMP SYSTEMS AS MISBRANDED, DANGEROUS AND “CAUSING DEATHS”